AGLE Aeglea BioTherapeutics, Inc.

6.90
0  -1%
Previous Close 7.00
Open 7.02
Price To book 1.49
Market Cap 92.82M
Shares 13,452,000
Volume 23,287
Short Ratio 0.34
Av. Daily Volume 100,255

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102
Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)
Phase 1 top-line data presented March 23, 2017.
AEB1102
Arginase I deficiency

SEC Filings

  1. CT ORDER - Confidential treatment order 17781820
  2. DEF 14A - Other definitive proxy statements 17774240
  3. 8-K - Current report 17774236
  4. 8-K - Current report 17711206
  5. S-8 - Securities to be offered to employees in employee benefit plans 17709843
  6. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17709822
  7. 8-K - Current report 17709791
  8. 8-K - Current report 17708185
  9. 8-K - Current report 17667825
  10. 8-K - Current report 17618609